Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.

[1]  C. Williamson,et al.  Prevalence of genotypic resistance to antiretroviral drugs in treatment-naive youths infected with diverse HIV type 1 subtypes and recombinant forms in Dar es Salaam, Tanzania. , 2011, AIDS research and human retroviruses.

[2]  W. Blattner,et al.  Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. , 2011, The Journal of infectious diseases.

[3]  H. Ding,et al.  Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. , 2010, Virology.

[4]  Jerome H. Kim,et al.  Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate , 2010, PloS one.

[5]  Jerome H. Kim,et al.  Prime–boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1 , 2010, Expert review of vaccines.

[6]  J. Excler.  HIV-vaccines: lessons learned and the way forward , 2010, Current opinion in HIV and AIDS.

[7]  E. Sandström,et al.  Strong HIV-Specific CD4+ and CD8+ T-Lymphocyte Proliferative Responses in Healthy Individuals Immunized with an HIV-1 DNA Vaccine and Boosted with Recombinant Modified Vaccinia Virus Ankara Expressing HIV-1 Genes , 2010, Clinical and Vaccine Immunology.

[8]  L. Buonaguro,et al.  Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. , 2010, The Lancet. Infectious diseases.

[9]  N. Frahm,et al.  Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies , 2010, AIDS.

[10]  M. Hoelscher,et al.  A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). , 2010, The Journal of infectious diseases.

[11]  Laurie Lamoreaux,et al.  Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses , 2010, PloS one.

[12]  D. Ho,et al.  Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 B'/C Candidate Vaccine , 2010, PloS one.

[13]  Yang Song,et al.  Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a Multigenic, DNA-Based Clade C/B' HIV-1 Candidate Vaccine , 2010, PloS one.

[14]  Jerome H. Kim,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[15]  S. Kochhar,et al.  A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. , 2009, AIDS research and human retroviruses.

[16]  P. Earl,et al.  Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. , 2009, Vaccine.

[17]  A. Thorson,et al.  Willingness to volunteer in a Phase I/II HIV vaccine trial: a study among police officers in Dar es Salaam, Tanzania , 2009, Global health action.

[18]  P. Earl,et al.  Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. , 2009, Vaccine.

[19]  Devan V Mehrotra,et al.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.

[20]  P. Earl,et al.  Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. , 2008, The Journal of infectious diseases.

[21]  B. Guy,et al.  Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice , 2008, Expert review of vaccines.

[22]  S. McCormack,et al.  EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. , 2008, Vaccine.

[23]  David C Montefiori,et al.  Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. , 2008, Virology.

[24]  P. Kaleebu,et al.  Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. , 2008, Vaccine.

[25]  C. Nilsson,et al.  Optimal Blood Mononuclear Cell Isolation Procedures for Gamma Interferon Enzyme-Linked Immunospot Testing of Healthy Swedish and Tanzanian Subjects , 2008, Clinical and Vaccine Immunology.

[26]  S. McCormack,et al.  An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses , 2008, The Journal of experimental medicine.

[27]  P. Earl,et al.  A New Multi-clade DNA Prime/Recombinant MVA Boost Vaccine Induces Broad and High Levels of HIV-1-specific CD8+ T-cell and Humoral Responses in Mice. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  R. Wyatt,et al.  Inhibition of HIV‐1 entry by antibodies: potential viral and cellular targets , 2007, Journal of internal medicine.

[29]  S. Rybak,et al.  Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. , 2007, Virology.

[30]  J. Mascola,et al.  Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. , 2007, Vaccine.

[31]  R. Koup,et al.  Safety and Immunogenicity of a Gag-Pol Candidate HIV-1 DNA Vaccine Administered by a Needle-Free Device in HIV-1-Seronegative Subjects , 2007, Journal of acquired immune deficiency syndromes.

[32]  Punnee Pitisuttithum,et al.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. , 2006, The Journal of infectious diseases.

[33]  J. Mascola,et al.  Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. , 2006, The Journal of infectious diseases.

[34]  J. Mascola,et al.  Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. , 2006, The Journal of infectious diseases.

[35]  E. Lyamuya,et al.  Evaluation of HIV antibody and antigen/antibody combination ELISAs for use in an alternative confirmatory HIV testing strategy in Dar es Salaam, Tanzania. , 2006, Journal of virological methods.

[36]  Gary J. Nabel,et al.  Preserved CD4+ Central Memory T Cells and Survival in Vaccinated SIV-Challenged Monkeys , 2006, Science.

[37]  K. Ljungberg,et al.  Reduced cellular immune responses following immunization with a multi-gene HIV-1 vaccine. , 2006, Vaccine.

[38]  Lucy Dorrell,et al.  Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA- and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing HIV-1 Gag Coupled to CD8+ T-Cell Epitopes , 2006, Journal of Virology.

[39]  K. Ljungberg,et al.  Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[40]  E. Sanders-Buell,et al.  Biologic and Genetic Characterization of a Panel of 60 Human Immunodeficiency Virus Type 1 Isolates, Representing Clades A, B, C, D, CRF01_AE, and CRF02_AG, for the Development and Assessment of Candidate Vaccines , 2005, Journal of Virology.

[41]  H. Robinson,et al.  T cell vaccines for microbial infections , 2005, Nature Medicine.

[42]  Michael G Hudgens,et al.  Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. , 2005, The Journal of infectious diseases.

[43]  D. Montefiori,et al.  Evaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene Assays , 2004, Current protocols in immunology.

[44]  Renate Kunert,et al.  Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies , 2004, Journal of Virology.

[45]  M. Hoelscher,et al.  HIV type 1 subtypes among blood donors in the Mbeya region of southwest Tanzania. , 2004, AIDS research and human retroviruses.

[46]  J. Heeney,et al.  Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen. , 2004, The Journal of general virology.

[47]  D. Swerdlow,et al.  Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. , 2004, Journal of the American College of Cardiology.

[48]  J. Atwood,et al.  Smallpox vaccination and myopericarditis: a clinical review. , 2004, Journal of the American College of Cardiology.

[49]  K. Ljungberg,et al.  Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. , 2002, Virology.

[50]  Sylvia Janetzki,et al.  A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. , 2002, Journal of immunological methods.

[51]  K. Pallangyo,et al.  The prevalence and incidence of HIV-1 infection and syphilis in a cohort of police officers in Dar es Salaam, Tanzania: a potential population for HIV vaccine trials , 2000, AIDS.

[52]  Kanakatte Raviprakash,et al.  Needle-free injection of DNA vaccines: a brief overview and methodology. , 2006, Methods in molecular medicine.